Mocertatug rezetecan(GlaxoSmithKline)은 Ovarian Neoplasms 표적 ADC로, Ovarian Neoplasms 영역에서 개발·상용화 중입니다. 작용기전: targeting the human epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 6건의 관련 임상이 등록되어 있습니다. 차별점: novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of.
Ovarian Neoplasms
Ovarian Neoplasms
Recruiting
ADC) targeting the human epidermal growth factor receptor 2 (HE
rezetecan
cleavable linker and delivers the topoisomerase I inhibi
humanized antibody-drug conjugates (ADCs) with chemical linkers and cytotoxic payloads have been developed fo
novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of
targeting the human epidermal growth factor receptor
topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of approximately 6
HER2-positive
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Mocertatug rezetecan(GlaxoSmithKline)은 Ovarian Neoplasms 표적 ADC로, Ovarian Neoplasms 영역에서 개발·상용화 중입니다. 작용기전: targeting the human epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 6건의 관련 임상이 등록되어 있습니다. 차별점: novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of.
Ovarian Neoplasms
Ovarian Neoplasms
Recruiting
ADC) targeting the human epidermal growth factor receptor 2 (HE
rezetecan
cleavable linker and delivers the topoisomerase I inhibi
humanized antibody-drug conjugates (ADCs) with chemical linkers and cytotoxic payloads have been developed fo
novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of
targeting the human epidermal growth factor receptor
topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of approximately 6
HER2-positive
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.